Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.33 |
| ▸ | TYR | P14679 | 3/20 | 0.33 |
| ▸ | ACLY | P53396 | 1/20 | 0.30 |
| ▸ | ACACA | Q13085 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24068231 | 0.88 | HSD11B1 (0.44) | HSD11B1HSD11B2PPARGPSEN1PSEN2 | |
| SCHEMBL19647510 | 0.85 | TYR (0.40) | TYR | |
| SCHEMBL16063114 | 0.78 | TYR (0.55) | HSD11B1HSD11B2PSEN1PSEN2APH1B | |
| SCHEMBL12332641 | 0.78 | TYR (0.55) | HSD11B1HSD11B2PSEN1PSEN2APH1B | |
| SCHEMBL4232635 | 0.74 | HSD11B1 (0.52) | HSD11B1HSD11B2PPARGPSEN1PSEN2 | |
| SCHEMBL29925026 | 0.74 | HSD11B1 (0.52) | HSD11B1HSD11B2PPARGPSEN1PSEN2 | |
| SCHEMBL4232633 | 0.74 | HSD11B1 (0.52) | HSD11B1HSD11B2PPARGPSEN1PSEN2 | |
| SCHEMBL24068239 | 0.73 | HSD11B1 (0.43) | HSD11B1HSD11B2PPARGPSEN1PSEN2 | |
| SCHEMBL19647469 | 0.70 | TYR (0.41) | PPARGPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL24068242 | 0.69 | HSD11B1 (0.45) | HSD11B1HSD11B2PPARGPSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003628-B2 | Methods of inhibiting osteoclast activity | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2011-08-23 | — | — | US | disclosed |
| US-20090306030-A1 | Methods Of Inhibiting Osteoclast Activity | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2009-12-10 | — | — | US | disclosed |
| US-7566741-B2 | Methods of inhibiting osteoclast activity | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2009-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306030-A1 | Methods Of Inhibiting Osteoclast Activity | NFATC1, CD40LG, CD14 | HSD11B1 3360/4885HSD11B2 3407/4885PPARG 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.